Clinical Trial Update: Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial [Phase 2]

View source ↗

Summary

A Phase II clinical trial assesses the combination of bevacizumab and erlotinib in patients with non-small cell lung cancer that has metastasized to the brain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms | Phase 2 | Status: UNKNOWN